There are many new immunotherapeutic drugs for cancer in the research pipeline. Too few patients are available to fill the clinical trials, as many are receiving treatment from physicians outside of the research institutions where trials are being held. In addition, many pharmaceutical companies are researching similar drugs, meaning there can be significant competition for the patients who are available. How should this problem be solved? http://nyti.ms/2v5A89E
- What information can the donation of one patient’s tumor yield about metastasis?
- What is the iMPACT Program and how will it bring diversity to clinical trials?
- How is it possible that a great many promising cancer drugs create a problem for research and trials?
- Research Ethics Education a critical priority for WCGF: New Grant Opportunities Offered.
- How are physicians and researchers working to make clinical trials more diverse?